126. Familial Pediatric Onset Multiple Sclerosis: A Retrospective Single-Center Observational Study

Mohamed Slim Majoul,Abir Zioudi,Thouraya Ben Younes,Hedia Klaa,Zouhour Miladi,Maha Jamoussi,Ilhem Ben Youssef-Turki,Hanene Ben Rhouma,Ichraf Kraoua
DOI: https://doi.org/10.1016/j.msard.2024.106087
IF: 4.808
2024-12-15
Multiple Sclerosis and Related Disorders
Abstract:Background/Objective(s) Familial recurrence in multiple sclerosis (MS) has been vastly studied. Genetic and environmental factors have been identified. However, few studies have described this phenomenon in pediatric onset multiple sclerosis (POMS) and its impact on clinical and prognostic profile. Material(s) and Method(s) A single-center retrospective observational descriptive study was conducted in the pediatric neurology department at the national institute Mongi Ben Hmida of Neurology of Tunis including patients meeting the 2017 McDonald criteria for relapsing-remitting MS with an age at onset before 18 years and another affected family member (AFM) to the third degree or less. Highly-active MS (HAMS) was defined according to MENACTRIMS guidelines (2024). Multiple sclerosis severity scale (MSSS) was calculated in POMS patients and their AFM. Rapid progressors were defined by a MSSS ≥ 5 and slow progressors were defined by MSSS < 5. Their demographic, clinical, radiological and evolutionary data were collected and analyzed. Result(s) Nine patients were included. Sex-ratio was 0.13. Age at onset varied from seven to 17 years. Seven patients had HAMS. In these cases, aggressive MS was noted in five AFM. Both HAMS patients and their AFM were treated by interferons and then switched to Natalizumab or Fingolimod. Time to escalation was one to three years longer in POMS than in AFM. MSSS was similar between POMS patients and their AFM with variation less than 1 in all cases. Rapid progressors accounted for five POMS cases. All of them had a rapid progressor AFM. Conclusion(s) Our study demonstrated a similar phenotype between index cases and affected relatives. In fact, POMS patients with a HAMS phenotype had AFM with a similar disease presentation. These similarities plead for a genetic contribution to the risk of developing a HAMS. More genetic research using genome wide association studies and new generation sequencing are needed to identify factors involved in MS pathogenesis in these patients. Treatment strategies were similar in POMS patients and their AFM with a longer delay to escalation in the former group. This is due to absence of approval for most second line disease-modifying therapies for pediatric patients. Larger-scale studies of familial MS cases are needed to identify prognostic factors and develop adequate treatment strategies for these patients.
clinical neurology
What problem does this paper attempt to address?